21 U.S. Code § 360n–1 - Priority review for qualified infectious disease products

prev | next
If the Secretary designates a drug under section 355f(d) of this title as a qualified infectious disease product, then the Secretary shall give priority review to any application submitted for approval for such drug under section 355 (b) of this title.


(June 25, 1938, ch. 675, § 524A, as added Pub. L. 112–144, title VIII, § 802(a),July 9, 2012, 126 Stat. 1079.)
Effective Date

Pub. L. 112–144, title VIII, § 802(b),July 9, 2012, 126 Stat. 1079, provided that: “Section 524A of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 360n–1], as added by subsection (a), applies only with respect to an application that is submitted under section 505(b) of such Act (21 U.S.C. 355 (b)) on or after the date of the enactment of this Act [July 9, 2012].”


LII has no control over and does not endorse any external Internet site that contains links to or references LII.